Related Experiment Video
Updated: Dec 25, 2025

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
Integrative analysis of genomic amplification-dependent expression and loss-of-function screen identifies ASAP1 as a
Jichao He1, Ronan P McLaughlin1, Lambert van der Beek1
1Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, 2300 RA, Leiden, The Netherlands.
Abstract:
The genetically heterogeneous triple-negative breast cancer (TNBC) continues to be an intractable disease, due to lack of effective targeted therapies. Gene amplification is a major event in tumorigenesis. Genes with amplification-dependent expression are being explored as therapeutic targets for cancer treatment. In this study, we have applied Analytical Multi-scale Identification of Recurring Events analysis and transcript quantification in the TNBC genome across 222 TNBC tumors and identified 138 candidate genes with positive correlation in copy number gain (CNG) and gene expression. siRNA-based loss-of-function screen of the candidate genes has validated EGFR, MYC, ASAP1, IRF2BP2, and CCT5 genes as drivers promoting proliferation in different TNBC cells. MYC, ASAP1, IRF2BP2, and CCT5 display frequent CNG and concurrent expression over 2173 breast cancer tumors (cBioPortal dataset). More frequently are MYC and ASAP1 amplified in TNBC tumors (>30%, n = 320). In particular, high expression of ASAP1, the ADP-ribosylation factor GTPase-activating protein, is significantly related to poor metastatic relapse-free survival of TNBC patients (n = 257, bc-GenExMiner). Furthermore, we have revealed that silencing of ASAP1 modulates numerous cytokine and apoptosis signaling components, such as IL1B, TRAF1, AIFM2, and MAP3K11 that are clinically relevant to survival outcomes of TNBC patients. ASAP1 has been reported to promote invasion and metastasis in various cancer cells. Our findings that ASAP1 is an amplification-dependent TNBC driver gene promoting TNBC cell proliferation, functioning upstream apoptosis components, and correlating to clinical outcomes of TNBC patients, support ASAP1 as a potential actionable target for TNBC treatment.
Insights
Triple-negative breast cancer (TNBC) lacks targeted therapies. This study identifies ASAP1 as an amplification-driven gene promoting TNBC proliferation and metastasis, suggesting it as a potential therapeutic target for this intractable disease.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Triple-negative breast cancer (TNBC) is a heterogeneous and aggressive cancer subtype with limited targeted treatment options.
- Gene amplification, leading to increased gene expression, is a significant driver in tumorigenesis and a potential therapeutic vulnerability.
Purpose of the Study:
- To identify and validate novel therapeutic targets for TNBC by analyzing amplification-dependent gene expression.
- To investigate the role of identified candidate genes in TNBC proliferation, survival, and clinical outcomes.
Main Methods:
- Applied Analytical Multi-scale Identification of Recurring Events (AMIIRE) and transcript quantification to 222 TNBC tumors.
- Conducted siRNA-based loss-of-function screens to validate candidate driver genes.
- Analyzed gene copy number gain (CNG) and expression data across large breast cancer datasets (cBioPortal, bc-GenExMiner).
Main Results:
- Identified 138 candidate genes with copy number gain and correlated gene expression in TNBC.
- Validated EGFR, MYC, ASAP1, IRF2BP2, and CCT5 as proliferation drivers in TNBC cells.
- ASAP1 amplification and high expression strongly correlate with poor metastatic relapse-free survival in TNBC patients and modulate key survival signaling pathways.
Conclusions:
- ASAP1 is an amplification-dependent driver gene in TNBC, promoting proliferation and influencing patient survival.
- ASAP1's role in modulating cytokine and apoptosis signaling pathways makes it a promising actionable therapeutic target for TNBC treatment.
More Related Videos
10:32Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
Published on: December 19, 2019
09:08Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
Related Concept Videos
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...